John Hancock becomes the first life insurance carrier to offer access to GRAIL’s multi-cancer early detection test to customers – PR Newswire

Highlights power of strategic industry partnerships to promote preventive health and empower well-being  

BOSTON , Sept. 20, 2022 /PRNewswire/ —  Today, Steve Hancock , the US division associated with Toronto -based Manulife (  NYSE: MFC ), announced it is offering access to GRAIL’s Galleri ® multi-cancer early detection test  to a pilot group of existing clients through the David Hancock Vitality Program, in collaboration with reinsurer Munich Re Life US. As the 1st life insurance carrier in order to make this breakthrough screening technology available, John Hancock is enabling eligible customers to take proactive steps to better understand and make more informed choices about their health.

According to the American Cancer Society, more than 600, 000 people die from cancer each year in the United States and many cancers show no symptoms until later stages, when treatment options may be limited. 1 Early detection associated with cancer can improve malignancy outcomes, yet today, many cancers are detected in late stages because only five types have recommended screenings — breast, cervical, colon, lung, and prostate cancers.  

John Hancock Vitality   is obtainable with the company’s life insurance coverage policies — offering education, support, incentives, plus rewards to encourage clients to take everyday steps toward a longer, healthier, better life. The Galleri test, the particular newest feature to be added to the program for eligible customers, is a first-of-its-kind multi-cancer early recognition blood check. In a clinical study , the Galleri test demonstrated the ability to detect a signal from a lot more than 50 types of malignancies, over 45 of which lack recommended screening tests. The test can also help determine where in the body cancer might be located, which can then guide diagnostic follow up.

“At Ruben Hancock, we are deeply invested in helping our customers live longer, more healthy, better lives. Almost everyone has experienced the devastating effects of cancer in some way and by making this early testing technology accessible, we may help change the malignancy narrative for some of our own customers, ” said Brooks Tingle , President plus CEO of John Hancock Insurance. “As a life insurer, we can use our unique position to make a powerful impact. As such,   we are bringing together carriers, distributors, reinsurers, and innovative technology companies in order to transform the customers’ experience while empowering them along with knowledge about their own health, ultimately improving lives. ”

Individual test results will not be shared with Bob Hancock and will have zero impact on the customer’s current life insurance coverage or pricing, or even status within the Energy program. Mark Hancock has partnered with GRAIL’s exclusive reinsurance partner, Munich Re Life ALL OF US, to bring this providing to life insurance coverage customers with regard to the first time, along with support through Swiss Lso are and SCOR. John Hancock has also collaborated with M Financial Group, an early companion of GRAIL.

“This collaboration amongst forward-thinking organizations, within the insurance business, highlights the power of strategic industry partners rallying around an aligned mission to help fight cancer, ” said Bob Ragusa , Chief Executive Officer at GRAIL. “With this particular initiative by John Hancock to make Galleri offered to eligible customers, as a complement to other cancer screenings, we can  help  change the status quo and  continue in our goal to  dramatically increase malignancy detection from screening in the population to improve public health. inch

Marc Giguere , President and CEO of Munich Re Existence US commented, “Munich Re Life US has a responsibility to society to assist advance early cancer detection plus treatments that produce much better outcomes regarding cancer patients. With this partnership, we have been helping to bridge the gap between medical research and advancements plus their effect on life insurance policy by bringing innovative solutions to our carrier companions. Munich Lso are Life US is incredibly proud to embark on this journey with GRAIL and Sara Hancock . ”

Through this pilot, John Hancock will assess customer adoption of Galleri, as well as the overall user encounter, before deciding how best to offer the test in the future. The Galleri test does not replace suggested routine malignancy screenings.

  1. Cancer Facts and Figures 2021 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

Disclaimer

Galleri is a registered trademark of GRAIL, LLC (“Grail”). The test is manufactured and distributed by GRAIL. John Hancock is not an affiliate associated with GRAIL. Tom Hancock does not provide medical advice and is not really responsible for the particular accuracy or performance of the Galleri test. There is no coordination between any health benefits you may receive through an insurance policy, wellness plan, or even any other wellness programs you might be enrolled in.

Galleri is not a test to confirm or rule out genetic or some other conditions that will may indicate a predisposition to cancer.   It is important to underscore that Galleri is just not a means of diagnosis, but rather a tool to help individuals screen for malignancy earlier . The Galleri test will not replace recommended routine cancer screenings.   The Galleri test has not been cleared or even approved simply by the Food and Drug Administration, but has received the breakthrough device designation by the FDA. GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) plus accredited by the College associated with American Pathologists (CAP). Because GRAIL pursues FDA approval, they have launched Galleri as a Laboratory Developed Test in compliance with applicable regulatory requirements, backed simply by evidence.  

The Galleri test is only available to registered Kim Hancock Vigor PLUS members who are usually 50 years of age or older, have completed the Vitality Health Review (VHR) intended for the present program 12 months, and whose policies were issued among 9/1/2019 and 3/31/2022 . For qualified policies along with coverage amounts of $500, 500 or greater, 100% of the cost of the test will be subsidized. For guidelines with less than $500, 000 in coverage, 50% off the cost of the particular test will be backed.

The Galleri test through The John Hancock Vitality Program is not currently available within ID, ND, NM, NY or VT.

Insurance products are issued by: Diane Hancock Lifestyle Insurance Company ( U. S. A. ), Boston, MA 02116 (not licensed in New York ) and Nicole Hancock Life Insurance Company of New York , Valhalla, NY 10595

Important Safety Information

The particular Galleri check is suggested for use in adults with an elevated risk to get cancer, this kind of as those aged fifty or old. The Galleri test does not detect all cancers and should be used in addition to routine cancer verification tests recommended by a healthcare provider. Galleri is intended to identify cancer plus predict where in your body the cancer signal is located. Use of Galleri is not really recommended in individuals who are pregnant, 21 many years old or younger, or even undergoing active cancer therapy.

Results should be interpreted by a healthcare provider in the context of healthcare history, medical signs and symptoms. A test result associated with “Cancer Signal Not Detected” will not rule out malignancy. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e. g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the malignancy being located in a different part of the body. False-positive (a cancer signal detected when cancer is just not present) and false-negative (a cancer transmission not detected when cancer is present) test results do occur. Rx only.

About John Hancock and Manulife

John Hancock is an unit associated with Manulife Financial Corporation,   a leading international financial services provider  that helps people  make their decisions easier and lives better by providing financial advice, insurance, and wealth and asset management solutions.   Manulife Financial Corporation trades as MFC on the TSX, NYSE, and PSE, and under 945 around the SEHK. Manulife can be found at manulife. com .

One of the largest life insurers inside the United States , John Hancock supports more than ten million Americans with a broad range of monetary products, which includes life insurance coverage and annuities . John Hancock also supports US investors simply by bringing leading investment capabilities and retirement planning plus administration expertise to individuals and institutions. Additional information about John Hancock may be found at johnhancock. com

Regarding Vitality

Guided by a core purpose of making people healthier, Vitality is the leader in improving health to unlock outcomes that matter. By blending industry-leading smart tech, data, incentives, and behavioral science, we inspire healthy changes in individuals and their organizations. As one of the largest wellness companies in the world, Vitality brings a dynamic plus diverse perspective through successful partnerships along with the most forward-thinking insurers and employers. More than 20 million individuals in 31 markets engage in the particular Vitality program. For more information, visit vitalitygroup. possuindo or follow us on Twitter and LinkedIn.

Energy is the provider of the Steve Hancock Energy Program in connection with policies issued by David Hancock . John Hancock Vitality Program rewards plus discounts are available only in order to the person insured under the eligible life insurance policy, may vary based on the type associated with insurance policy purchased and the state where the policy was released, are subject to change and are not guaranteed to remain the same for the existence of the policy.

Insurance policies and/or associated riders and features may not be available in all states.

About Munich Re Life US

As one of the particular leading lifestyle reinsurers within the Usa States,   Munich Re Life US  partners with insurers to leverage smart and connected data, embrace new ideas and technologies, make confident decisions in speed and scale, plus gain a good exponential understanding of underlying risks. Munich Lso are Life US is well known in the industry as an innovation leader with extensive technical depth. Its optimized solutions and capital management expertise expand beyond market leading offerings in individual life, group, individual disability and living benefits reinsurance, to a global center for predictive analytics, automated underwriting, digital partnerships and standard-setting underwriting plus medical abilities. Munich Re Life US believes the digital economy offers an unprecedented opportunity for the particular life insurance policy industry in order to rapidly advance risk assessment and close the widening global underinsured gap.

Munich Re Existence US, incorporated as Munich American Reassurance Company, is a subsidiary of Münchener Rückversicherungs- Gesellschaft Aktiengesellschaft in München (“Munich Re”). It has high ratings for economic strength from A. M. Best Company and Standards & Poors. Munich Lso are Life US ALL serves clients throughout the United States from its two locations in New York and Atlanta .

About GRAIL

GRAIL is really a healthcare company whose mission is to detect cancer early, whenever it can be cured. GRAIL is focused on alleviating the global burden of malignancy by developing pioneering technology to identify and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and in order to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D. C. , North Carolina , and the particular United Kingdom . GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN ) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021 .

For more information, visit grail. com.

About Galleri®

The earlier that cancer is detected, the higher the particular chance associated with successful outcomes. The Galleri multi-cancer earlier detection test can detect signals across more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, through a routine blood draw. When a cancer signal is recognized, the Galleri test predicts the malignancy signal origin, or helps to determine where the particular cancer is located in the body, with high accuracy to help guide the next steps to diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used inside addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical malignancy screening. It is intended for use in people with an elevated risk of cancer, such as those aged 50 or even older.

For more information about Galleri, visit galleri. com.
MLINY091422686-1 

SOURCE John Hancock

Leave a Reply

Your email address will not be published.